ストックスクリーナーアプリを入手
0.721
0.55%
-0.004
前日終値:
$0.725
開ける：
$0.75
24時間の取引高:
110.17K
Relative Volume:
0.28
時価総額：
$23.11M
収益：
-
当期純損益:
$-51.23M
株価収益率:
-0.559
EPS:
-1.2898
ネットキャッシュフロー:
$-41.53M
1週間 パフォーマンス:
-9.82%
1か月 パフォーマンス:
-23.39%
6か月 パフォーマンス:
-77.82%
1年 パフォーマンス:
-74.70%
1日の値動き範囲:
$0.7182
$0.7548
1週間の範囲:
$0.6853
$0.84
52週間の値動き範囲:
$0.6844
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
名前
Skye Bioscience Inc
セクター
電話
(858) 410-0266
住所
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
2.22 | 3.25B | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
8.69 | 536.01M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.32 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
2.8999 | 277.51M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
46.01 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-06 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | ダウングレード | Craig Hallum | Buy → Hold |
| 2025-08-15 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-09-30 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-09 | 開始されました | Craig Hallum | Buy |
| 2024-05-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-04-12 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Skye Bioscience Inc (SKYE) 最新ニュース
Geopolitics Watch: Does Skye Bioscience Inc meet Warren Buffetts criteriaQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscience, Inc. (SKYE) And Encourages Shareholders to Connect | NDAQ:SKYE | Press Release - Stockhouse
Aug EndMonth: How does IHS Holding Limited compare to its peersJuly 2025 Institutional & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Whats the outlook for Skye Bioscience Incs sectorTrade Analysis Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Retail Trends: Does Skye Bioscience Inc have a competitive edgeJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Aug Analyst Calls: Will Skye Bioscience Inc benefit from government policy2025 Valuation Update & Precise Trade Entry Recommendations - baoquankhu1.vn
Movement Recap: Can Skye Bioscience Inc weather a recessionMarket Rally & Long-Term Capital Growth Strategies - baoquankhu1.vn
Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely - Sahm
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 - Investing.com Australia
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating - TipRanks
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Benzinga
Skye Bioscience (SKYE) Reports Promising Results from CBeyond Ex - GuruFocus
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab - TipRanks
Skye reports positive Cbeyond phase 2a extension interim study results for nimacimab - marketscreener.com
Skye Bioscience Reports Interim Results from Phase 2a Study of Nimacimab - TradingView
Skye, Inc. Announces Interim Results from the Combination Cohort of the Company's Phase 2A Extension Study of Nimacimab - marketscreener.com
Obesity drug combo keeps weight off: Skye study shows 22.3% loss - Stock Titan
Chart Watch: Can Skye Bioscience Inc weather a recessionWeekly Trend Summary & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Skye Reports Positive CBeyond Phase 2a Extension Interim - GlobeNewswire
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period - MSN
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Skye Bioscience reports positive results for obesity drug nimacimab By Investing.com - Investing.com South Africa
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Skye Bioscience reports positive results for obesity drug nimacimab - Investing.com
Skye Bioscience (SKYE) Highlights Promising Obesity Treatment Re - GuruFocus
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - The Manila Times
Skye Bioscience Highlights Attributes of its - GlobeNewswire
Investment Report: Can Skye Bioscience Inc beat the S P 500Earnings Miss & Safe Capital Growth Stock Tips - baoquankhu1.vn
Portfolio Shifts: Will CREG stock hit new highs in YEARJuly 2025 WrapUp & Smart Money Movement Tracker - baoquankhu1.vn
2026-01-27 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Stockholders to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Revenue Check: Can Skye Bioscience Inc beat the S P 5002025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Investors to Inquire about Securities Investigation - accessnewswire.com
2026-01-25 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Investors to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Aug Retail: Can Skye Bioscience Inc weather a recessionEarnings Recap Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
Skye Bioscience to Present Research on Nimacimab at Keystone Conference on Obesity Therapeutics - Quiver Quantitative
Skye Bioscience to Present Poster at Keystone Obesity Conference - The Manila Times
Resistance Check: Will Skye Bioscience Inc outperform the market in YEAR2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Skye Bioscience, Inc. (SKYE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Skye Bioscience Faces Class Action for Securities Fraud, Investors Encouraged to Join - Intellectia AI
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Se - GuruFocus
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SKYE DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Skye Bioscience, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bios - GuruFocus
Skye Bioscience, Inc. Class Action Reminder: Lead Plaintiff Deadline January 16, 2026 - Intellectia AI
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit - Prime Publishers, Inc.
Skye Bioscience, Inc. (NASDAQ: SKYE) Investor NOTICE: Deadline in Lawsuit on January 16, 2026 - openPR.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - TMX Newsfile
Skye Bioscience Inc (SKYE) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):